Tag Archives: NPK

Hot High Tech Stocks For 2019

Honeywell (NYSE: HON) and Gentherm (NASDAQ:THRM) are both multi-sector conglomerates companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, profitability, valuation and risk.

Institutional and Insider Ownership

Get Honeywell alerts:

74.3% of Honeywell shares are held by institutional investors. Comparatively, 98.7% of Gentherm shares are held by institutional investors. 1.3% of Honeywell shares are held by insiders. Comparatively, 2.3% of Gentherm shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Honeywell and Gentherm’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Honeywell $40.53 billion 2.77 $1.66 billion $7.11 21.13
Gentherm $985.68 million 1.37 $35.22 million $2.31 15.87

Honeywell has higher revenue and earnings than Gentherm. Gentherm is trading at a lower price-to-earnings ratio than Honeywell, indicating that it is currently the more affordable of the two stocks.

Hot High Tech Stocks For 2019: Archrock, Inc.(AROC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Archrock (NYSE:AROC) posted its quarterly earnings data on Tuesday. The energy company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02, Briefing.com reports. The firm had revenue of $233.20 million during the quarter, compared to analysts’ expectations of $232.15 million. Archrock had a net margin of 6.32% and a return on equity of 2.49%. The business’s revenue was up 11.6% compared to the same quarter last year.

  • [By ]

    As it happens, I am familiar with about half of these stocks. Archrock (Nasdaq: AROC), Qualcomm (Nasdaq: QCOM), Schlumberger (NYSE: SLB, and Trinity Industries (NYSE: TRN) are all interesting names that I’ve either owned in the past or have written about recently over at High-Yield Investing.

  • [By Tyler Crowe]

    Oil and gas infrastructure specialist Archrock (NYSE:AROC) and its former subsidiary Archrock Partners were once a textbook case of an overaggressive business that got rocked by crashing oil and gas prices. The company bet heavily on the need for compression horsepower to force oil and gas from wells to pipelines, and took on considerable leverage to do so. When demand dried up from lower production volumes, Archrock was stuck with a fleet of inactive compression equipment and a massive debt load.

Hot High Tech Stocks For 2019: General American Investors, Inc.(GAM)

Advisors’ Opinion:

  • [By Max Byerly]

    Gambit (CURRENCY:GAM) traded 7.4% lower against the US dollar during the 1 day period ending at 15:00 PM ET on September 4th. One Gambit token can now be purchased for about $4.78 or 0.00064993 BTC on popular exchanges. Gambit has a market cap of $5.52 million and $2,335.00 worth of Gambit was traded on exchanges in the last 24 hours. Over the last week, Gambit has traded 12.6% higher against the US dollar.

  • [By Joseph Griffin]

    Gambit (GAM) is a PoW/PoS token that uses the Scrypt hashing algorithm. Its genesis date was May 5th, 2015. Gambit’s total supply is 2,599,999 tokens and its circulating supply is 1,154,053 tokens. Gambit’s official Twitter account is @gambitcrypto. The official website for Gambit is www.gambitcrypto.com.

Hot High Tech Stocks For 2019: Evolving Systems, Inc.(EVOL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Evolving Systems (NASDAQ: EVOL) and Zscaler (NASDAQ:ZS) are both computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Hot High Tech Stocks For 2019: National Presto Industries, Inc.(NPK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    OppenheimerFunds Inc. cut its stake in shares of National Presto Industries Inc. (NYSE:NPK) by 62.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,899 shares of the conglomerate’s stock after selling 3,188 shares during the quarter. OppenheimerFunds Inc.’s holdings in National Presto Industries were worth $235,000 as of its most recent SEC filing.

  • [By Max Byerly]

    SG Americas Securities LLC increased its stake in shares of National Presto Industries Inc. (NYSE:NPK) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,628 shares of the conglomerate’s stock after acquiring an additional 247 shares during the quarter. SG Americas Securities LLC’s holdings in National Presto Industries were worth $307,000 at the end of the most recent quarter.

Hot High Tech Stocks For 2019: MannKind Corporation(MNKD)

Advisors’ Opinion:

  • [By Brian Feroldi]

    Investors in MannKind Corporation (NASDAQ:MNKD) are having another pleasant day. Shares were up 37% as of 10:05 a.m. EDT on Wednesday. That’s quite a bullish move for a single day, but it’s all the more impressive given that the stock also jumped 89% higher on Tuesday. 

  • [By Paul Ausick]

    Mannkind Corp. (NASDAQ: MNKD) traded down about 34% Friday to set a new 52-week low of $0.99. Shares closed at $1.50 on Thursday, and the 52-week high is $6.96. Volume was about five times the daily average of around 2 million. The struggling biopharma firm reported weak earnings last night.

  • [By Chris Lange]

    The number of MannKind Corp. (NASDAQ: MNKD) shares short decreased to 29.04 million. The previous reading was 30.26 million. The stock was last seen at $1.90 in a 52-week range of $1.09 to $6.96.

  • [By George Budwell]

    MannKind Corporation (NASDAQ:MNKD), the maker of the inhaled insulin product Afrezza, had yet another bad month in April. Specifically, the biotech’s shares lost a quarter of their value last month, according to S&P Global Market Intelligence. 

  • [By Chris Lange]

    The number of MannKind Corp. (NASDAQ: MNKD) shares short increased to 35.28 million. The previous reading was 27.67 million. The stock was last seen at $1.70, in a 52-week range of $1.09 to $6.96.

  • [By Todd Campbell]

    On the cusp of a cash crunch that could have threatened its survival, MannKind Corporation (NASDAQ:MNKD) secured $45 million in upfront cash from United Therapeutics (NASDAQ:UTHR) this week to develop an inhaled version of Remodulin, a top-selling drug for pulmonary arterial hypertension that’s losing patent exclusivity this year. The cash, plus an additional $10 million for an undisclosed drug development program, gives MannKind more time to grow sales of its inhaled insulin, Afrezza, but MannKind isn’t out of the woods yet. It’s still burning through cash, and that could cause problems for investors in 2019.